RU2019111357A - N3-циклически замещенные тиеноурацилы и их применение - Google Patents

N3-циклически замещенные тиеноурацилы и их применение Download PDF

Info

Publication number: RU2019111357A
Authority: RU; Russia
Prior art keywords: methyl; formula; cyclobutyl; cyclopropyl; cyclopentyl
Prior art date: 2016-09-23

Application number

RU2019111357A

Other languages

English (en)

Russian (ru)

Inventor

Михаэль Хертер

Дирк Коземунд

Гранде Йоланда Канчо

Мартина Дельбек

Бернд Кальтхоф

Клеменс ЛЮСТИГ

Франк Зюссмайер

Original Assignee

Байер Акциенгезельшафт

Байер Фарма Акциенгельшафт

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-09-23

Filing date

2017-09-18

Publication date

2020-10-23

2017-09-18 Application filed by Байер Акциенгезельшафт, Байер Фарма Акциенгельшафт filed Critical Байер Акциенгезельшафт

2020-10-23 Publication of RU2019111357A publication Critical patent/RU2019111357A/ru

Links

-1 cyano, methoxycarbonyl Chemical group 0.000 claims 45
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 29
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 22
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 20
229910052739 hydrogen Inorganic materials 0.000 claims 18
239000001257 hydrogen Substances 0.000 claims 18
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 16
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 12
229910052731 fluorine Inorganic materials 0.000 claims 12
239000011737 fluorine Substances 0.000 claims 12
150000001875 compounds Chemical class 0.000 claims 11
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 10
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 9
150000003254 radicals Chemical class 0.000 claims 8
HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 claims 6
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 6
229910052805 deuterium Inorganic materials 0.000 claims 6
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 6
229910052757 nitrogen Inorganic materials 0.000 claims 6
229910052760 oxygen Inorganic materials 0.000 claims 6
239000012453 solvate Substances 0.000 claims 6
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
201000003883 Cystic fibrosis Diseases 0.000 claims 4
206010019280 Heart failures Diseases 0.000 claims 4
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 4
206010028980 Neoplasm Diseases 0.000 claims 4
208000006673 asthma Diseases 0.000 claims 4
201000011510 cancer Diseases 0.000 claims 4
125000004093 cyano group Chemical group *C#N 0.000 claims 4
150000002431 hydrogen Chemical class 0.000 claims 4
208000036971 interstitial lung disease 2 Diseases 0.000 claims 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 4
208000010125 myocardial infarction Diseases 0.000 claims 4
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 4
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 4
230000002265 prevention Effects 0.000 claims 4
208000002815 pulmonary hypertension Diseases 0.000 claims 4
208000007056 sickle cell anemia Diseases 0.000 claims 4
208000011580 syndromic disease Diseases 0.000 claims 4
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 3
125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims 3
125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 3
239000003814 drug Substances 0.000 claims 3
206010006448 Bronchiolitis Diseases 0.000 claims 2
206010029888 Obliterative bronchiolitis Diseases 0.000 claims 2
201000003848 bronchiolitis obliterans Diseases 0.000 claims 2
208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims 2
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 2
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
229940126601 medicinal product Drugs 0.000 claims 2
238000000034 method Methods 0.000 claims 2
229910052717 sulfur Inorganic materials 0.000 claims 2
102000002045 Endothelin Human genes 0.000 claims 1
108050009340 Endothelin Proteins 0.000 claims 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 1
241001465754 Metazoa Species 0.000 claims 1
229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
108091006335 Prostaglandin I receptors Proteins 0.000 claims 1
239000012190 activator Substances 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
239000005557 antagonist Substances 0.000 claims 1
230000003510 anti-fibrotic effect Effects 0.000 claims 1
230000003110 anti-inflammatory effect Effects 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
229940127089 cytotoxic agent Drugs 0.000 claims 1
239000002254 cytotoxic agent Substances 0.000 claims 1
231100000599 cytotoxic agent Toxicity 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
230000002519 immonomodulatory effect Effects 0.000 claims 1
230000001506 immunosuppresive effect Effects 0.000 claims 1
229940125721 immunosuppressive agent Drugs 0.000 claims 1
239000003018 immunosuppressive agent Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
231100000252 nontoxic Toxicity 0.000 claims 1
230000003000 nontoxic effect Effects 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
150000003815 prostacyclins Chemical class 0.000 claims 1
239000000018 receptor agonist Substances 0.000 claims 1
229940044601 receptor agonist Drugs 0.000 claims 1
230000019491 signal transduction Effects 0.000 claims 1
239000000021 stimulant Substances 0.000 claims 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

RU2019111357A 2016-09-23 2017-09-18 N3-циклически замещенные тиеноурацилы и их применение RU2019111357A (ru)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP16190351		2016-09-23
EP16190351.3		2016-09-23
EP17179105		2017-06-30
EP17179105.6		2017-06-30
PCT/EP2017/073504 WO2018054846A1 (de)	2016-09-23	2017-09-18	N3-cyclisch substituierte thienouracile und ihre verwendung

Publications (1)

Publication Number	Publication Date
RU2019111357A true RU2019111357A (ru)	2020-10-23

Family

ID=59856541

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2019111357A RU2019111357A (ru)	2016-09-23	2017-09-18	N3-циклически замещенные тиеноурацилы и их применение

Country Status (16)

Country	Link
US (1)	US20200016159A1 (es)
EP (1)	EP3515919A1 (es)
JP (1)	JP2019529452A (es)
KR (1)	KR20190053242A (es)
CN (1)	CN109963858A (es)
AU (1)	AU2017329677A1 (es)
BR (1)	BR112019005795A2 (es)
CA (1)	CA3037642A1 (es)
IL (1)	IL265531A (es)
MX (1)	MX2019003351A (es)
PE (1)	PE20190474A1 (es)
RU (1)	RU2019111357A (es)
SG (1)	SG11201902588PA (es)
TW (1)	TW201825497A (es)
UY (1)	UY37415A (es)
WO (1)	WO2018054846A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2019367187A1 (en)	2018-10-24	2021-03-25	Leadxpro Ag	Functionalized aminotriazines
AU2021253571A1 (en) *	2020-04-08	2022-11-10	Remix Therapeutics Inc.	Compounds and methods for modulating splicing
CN111763218B (zh) *	2020-07-14	2021-05-28	山东大学	一种噻吩并嘧啶酮巯乙酸类衍生物及其制备方法与应用
US20240368190A1 (en) *	2023-04-14	2024-11-07	Revolution Medicines, Inc.	Synthesis of ras inhibitors
WO2025164717A1 (ja) *	2024-02-02	2025-08-07	株式会社萩原農場生産研究所	スイカ雄花から抽出した抗炎症組成物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6140325A (en)	1993-08-19	2000-10-31	Takeda Chemical Industries, Ltd.	Thienopyrimidine derivatives, their production and use
WO1998038176A1 (en)	1997-02-26	1998-09-03	Hokko Chemical Industry Co., Ltd.	1-substituted 4-carbamoyl-1,2,4-triazol-5-one derivatives and herbicide
SE9702001D0 (sv)	1997-05-28	1997-05-28	Astra Pharma Prod	Novel compounds
DE19834047A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Substituierte Pyrazolderivate
DE19834044A1 (de)	1998-07-29	2000-02-03	Bayer Ag	Neue substituierte Pyrazolderivate
DK1107973T3 (da)	1998-08-28	2004-02-23	Astrazeneca Ab	Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi
ES2254163T3 (es)	1999-04-09	2006-06-16	Cell Therapeutics, Inc.	Compuestos terapeuticos para inhibir la señalizacion de la interleucina-12 y metodos para el uso de la misma.
DE19943635A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de)	1999-09-13	2001-04-12	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de)	1999-09-13	2001-03-15	Bayer Ag	Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
GB2363377B (en) *	2000-06-14	2004-06-09	Astrazeneca Ab	Novel thieno[2,3-d]pyrimidinediones and therapeutic uses thereof
AR031176A1 (es)	2000-11-22	2003-09-10	Bayer Ag	Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002064598A1 (en)	2001-02-14	2002-08-22	Warner-Lambert Company Llc	Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
DE10110750A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de)	2001-03-07	2002-09-12	Bayer Ag	Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de)	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
WO2004014916A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Pyrimidine fused bicyclic metalloproteinase inhibitors
US6890923B2 (en)	2002-12-16	2005-05-10	Astrazeneca Ab	Compounds
WO2007103776A2 (en)	2006-03-02	2007-09-13	Cv Therapeutics, Inc.	A2a adenosine receptor antagonists
NZ573352A (en)	2006-06-08	2011-10-28	Lilly Co Eli	Substituted carboxamides as group i metabotropic receptor antagonists
WO2008070529A2 (en)	2006-12-01	2008-06-12	Cv Therapeutics, Inc.	A2a adenosine receptor antagonists
GB0718432D0 (en)	2007-09-21	2007-10-31	Vernalis R&D Ltd	New chemical compounds
DE102010021637A1 (de)	2010-05-26	2011-12-01	Bayer Schering Pharma Aktiengesellschaft	Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PH12013500055A1 (en)	2010-07-09	2017-08-23	Bayer Ip Gmbh	Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de)	2010-09-03	2012-03-08	Bayer Schering Pharma Aktiengesellschaft	Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de)	2010-11-04	2012-05-10	Bayer Schering Pharma Aktiengesellschaft	Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
UA123760C2 (uk)	2011-11-11	2021-06-02	Гіліад Аполло, Ллс	Сполука (варіанти) та композиція, що містить сполуку
CA2911818A1 (en)	2013-05-10	2014-11-13	Nimbus Apollo, Inc.	Acc inhibitors and uses thereof
WO2014182943A1 (en)	2013-05-10	2014-11-13	Nimbus Apollo, Inc.	Acc inhibitors and uses thereof
EA201600318A1 (ru) *	2013-10-07	2016-09-30	Байер Фарма Акциенгезельшафт	Циклические тиеноурацилкарбоксамиды и их применение
WO2016023832A1 (en)	2014-08-11	2016-02-18	Hydra Biosciences, Inc.	Thieno- and furo[2,3-d]pyrimidine-2,4[1h,3h]-dione derivatives as trpc5 modulators for the treatment of neuropsychiatric disorders
UY36586A (es)	2015-03-26	2016-10-31	Bayer Pharma AG	Heterociclilmetiltienouracilos y uso de los mismos
AR106472A1 (es)	2015-10-26	2018-01-17	Gilead Apollo Llc	Inhibidores de acc y usos de los mismos

2017
- 2017-09-18 PE PE2019000698A patent/PE20190474A1/es unknown
- 2017-09-18 AU AU2017329677A patent/AU2017329677A1/en not_active Abandoned
- 2017-09-18 BR BR112019005795A patent/BR112019005795A2/pt not_active Application Discontinuation
- 2017-09-18 KR KR1020197011123A patent/KR20190053242A/ko not_active Withdrawn
- 2017-09-18 RU RU2019111357A patent/RU2019111357A/ru not_active Application Discontinuation
- 2017-09-18 US US16/335,282 patent/US20200016159A1/en not_active Abandoned
- 2017-09-18 SG SG11201902588PA patent/SG11201902588PA/en unknown
- 2017-09-18 CN CN201780072526.2A patent/CN109963858A/zh active Pending
- 2017-09-18 WO PCT/EP2017/073504 patent/WO2018054846A1/de not_active Ceased
- 2017-09-18 CA CA3037642A patent/CA3037642A1/en not_active Abandoned
- 2017-09-18 MX MX2019003351A patent/MX2019003351A/es unknown
- 2017-09-18 JP JP2019515607A patent/JP2019529452A/ja active Pending
- 2017-09-18 EP EP17765199.9A patent/EP3515919A1/de not_active Withdrawn
- 2017-09-21 TW TW106132376A patent/TW201825497A/zh unknown
- 2017-09-22 UY UY0001037415A patent/UY37415A/es unknown
2019
- 2019-03-21 IL IL265531A patent/IL265531A/en unknown

Also Published As

Publication number	Publication date
AU2017329677A1 (en)	2019-04-18
PE20190474A1 (es)	2019-04-04
MX2019003351A (es)	2019-08-05
SG11201902588PA (en)	2019-05-30
US20200016159A1 (en)	2020-01-16
BR112019005795A2 (pt)	2019-06-18
CA3037642A1 (en)	2018-03-29
WO2018054846A1 (de)	2018-03-29
IL265531A (en)	2019-05-30
TW201825497A (zh)	2018-07-16
UY37415A (es)	2018-04-30
JP2019529452A (ja)	2019-10-17
EP3515919A1 (de)	2019-07-31
CN109963858A (zh)	2019-07-02
KR20190053242A (ko)	2019-05-17

Publication	Publication Date	Title
RU2019111357A (ru)	2020-10-23	N3-циклически замещенные тиеноурацилы и их применение
JP6933770B2 (ja)	2021-09-08	Ｈｉｖカプシド阻害剤のコリン塩形態
ES2746374T3 (es)	2020-03-05	Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección producida por el virus del VIH
JP2021191798A (ja)	2021-12-16	Ｈｉｖカプシド阻害剤の固体形態
AU2019307500B2 (en)	2022-09-29	Capsid inhibitors for the treatment of HIV
RU2017124136A (ru)	2019-02-11	Трициклическое спиро-соединение
JP2014533695A5 (es)	2016-04-07
JP2017522273A5 (es)	2018-07-12
JP2006504621A5 (es)	2006-04-13
JP2013527242A5 (es)	2014-07-17
WO2018049014A1 (en)	2018-03-15	Dash inhibitors, and uses related thereto
RU2003100504A (ru)	2004-07-10	Органические соединения
KR20210008070A (ko)	2021-01-20	신경 섬유 감작과 연관된 질환의 치료를 위한 1,3-티아졸-2-일 치환된 벤즈아미드
JP2018528229A5 (es)	2019-10-17
GT200500156A (es)	2006-01-10	Derivados de acido carboxilico de bencimidazolona
RU2013140793A (ru)	2015-03-20	Способы лечения легочной гипертензии
RU2015150287A (ru)	2017-06-28	Новые соединения 3,4-дигидро-2н-изохинолин-1-она и 2,3-дигидроизоиндол-1-она
JP2017533935A5 (es)	2018-12-27
CN111278465A (zh)	2020-06-12	mIDH1抑制剂和DNA低甲基化剂（HMA）的组合
JP2019026646A5 (es)	2021-08-19
JP6010614B2 (ja)	2016-10-19	血清尿酸を低下させるための［１，２，４］チアジアジン１，１−ジオキサイド化合物
KR20150135110A (ko)	2015-12-02	p-당단백질의 저해제 및 p-당단백질의 기질 약물을 포함하는 약제학적 조성물
JP2017514849A5 (es)	2018-06-14
HK40117895A (zh)	2025-05-30	用於预防性或治疗性治疗hiv病毒感染的治疗性化合物
HK40113830A (zh)	2025-02-21	桥连三环氨基甲酰基吡啶酮化合物及其用途

Legal Events

Date	Code	Title	Description
2022-01-27	FA93	Acknowledgement of application withdrawn (no request for examination)	Effective date: 20200921